Defining Translational Approaches for the Image-based Detection of Prenatal Alcohol Exposure

作为CIFASD5的一个组成部分，该项目将侧重于改进对 产前酒精暴露(PAE)的人，整个生命周期，主要目标是 翻译为临床应用。我们针对申请申请中概述的两个主要类别 (RFA)1.及早准确地识别FASD病例；2.扩展和翻译基本和 对PAE效应的机械论理解。为了解决这些问题，我们的目标是改善 FASD临床识别的准确性和可靠性，控制了性别、性别和性别的影响。 曝光量和年龄。我们试图更好地了解神经认知和面部形态 FASD的相关性和协变性，并利用这种关系来提高筛查的准确性。 此前，我们已经实现了分析人脸形状和人脸的方法和相关软件- 大脑-认知关系以检测PAE的影响。在这样做的过程中，我们创造了一个有效的 自动和客观地识别与PAE相关的主要和轻微面部畸形的工具包 在整个FASD频谱上。现在当务之急是改进和优化我们的方法，利用低成本 3D成像设备，用于验证并分发给临床社区。为了实现我们的目标，我们 建议遵循特定的目标： 1.探讨酒精暴露继发因素对面部形态的影响； 2.检测胎儿期酒精暴露对面部、颅脑和神经的影响； 3.开发、测试和验证FASD筛查的自动化方法，集成神经认知 评估工具并分发给临床社区。 通过了解以下因素，实现目标1和目标2将极大地改进FASD识别 仅次于酒精，这可能会影响一生的结果。成功演示 目标2将实现尽可能早的诊断，从而能够进行进一步的研究和反馈 干预性研究，也专注于识别成年人的特征--一个显著的群体 在文献中被低估了。最终，目标3包含了项目的主要目标， 开发、测试和验证有助于临床鉴定的多域筛查工具。 我们将与财团合作伙伴密切合作，他们将招募受试者并提供面部图像和 神经认知评估数据(U01：Chambers；U01：Coles&Weinberg；U01：Wozniak；U01： DiClemente；U01：Petrenko)。面部神经认知需要特别密切的合作 分析，我们将整合和结合面部和神经认知筛查工具(U01： 马特森)。我们将依靠研究资源进行数据管理(R24：Wetherill)并验证 筛查工具并获得临床反馈(R24：Del Campo)。

As a constituent component of CIFASD5, this project will focus on improving the identification of individuals with prenatal alcohol exposure (PAE), across the lifespan, with the primary goal of translation for clinical application. We target two main categories outlined in the Request for Application (RFA) 1. To identify FASD cases early and accurately, and 2. To expand and translate basic and mechanistic understandings of the effects of PAE. To address these topics, we aim to improve the accuracy and reliability of the clinical recognition of FASD, controlling for the influence of sex, co- exposures, and age. We seek to understand better how neurocognitive and facial morphology are correlative and covariant in FASD and exploit this relationship to improve screening accuracy. Previously, we have implemented methods and associated software for analyzing face shape and face - brain-cognitive relationships to detect the effects of PAE. In doing so, we have created an effective toolkit to automatically and objectively identify cardinal and subtle PAE-associated facial dysmorphism across the FASD spectrum. It is now a priority to refine and optimize our methods, utilizing low-cost 3D imaging devices to validate and distribute to the clinical community. To accomplish our goals, we propose to follow specific aims: 1. Explore the impact of factors secondary to alcohol exposure that may influence facial morphology; 2. Detect facial, cranial, and neural effects of prenatal alcohol exposure across the lifespan; 3. Develop, test, and validate automated methods for FASD screening, integrating neurocognitive assessment tools and distributing to the clinical community. Achieving aims 1 and 2 will dramatically refine FASD recognition by understanding the factors secondary to alcohol that may influence outcomes across the lifespan. Successful demonstration of aim 2 will achieve the earliest possible diagnosis enabling further research and feedback for intervention studies and also focus on recognizing traits in adults - a population significantly underreported in the literature. Ultimately, aim 3 encompasses the primary goal of the project, developing, testing, and validating multi-domain screening tools that assist with clinical identification. We will work closely with consortium partners who will recruit subjects and provide facial images and neurocognitive assessment data (U01: Chambers; U01: Coles & Weinberg; U01: Wozniak; U01: DiClemente; U01: Petrenko). Particularly close collaboration is required for the face-neurocognitive analysis, where we will integrate and combine facial and neurocognitive screening tools (U01: Mattson). We will rely on research resources for data management (R24: Wetherill) and to validate screening tools and gain clinical feedback (R24: Del Campo).